Application of fisetin in preparation of medicine for preventing and treating uric acid nephropathy

A technology for uric acid nephropathy and fisetin, which is applied in the field of medicine and can solve the problems that patients are not easily tolerated, and the clinical application of allopurinol is limited.

Inactive Publication Date: 2021-05-07
WEST CHINA HOSPITAL SICHUAN UNIV
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, allopurinol is the first-line drug used clinically to lower uric acid, but it can cause adverse reactions such as skin allergies and bone marrow suppression, especially Stevens-Johnson syndrome and toxic epidermal necrolysis, with a mortality rate of 10%. ~40%, these adverse reactions limit the clinical application of allopurinol to some extent
Moreover, allopurinol is metabolized by the kidneys. For patients with renal insufficiency, it is often necessary to adjust the dose according to the glomerular filtration rate, otherwise the patient is not easy to tolerate

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of fisetin in preparation of medicine for preventing and treating uric acid nephropathy
  • Application of fisetin in preparation of medicine for preventing and treating uric acid nephropathy
  • Application of fisetin in preparation of medicine for preventing and treating uric acid nephropathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Example 1 The effect of fisetin on preventing uric acid nephropathy

[0032] Experimental animals: SPF grade male C57BL / 6J mice. At least 1 week before the experiment, the rats were fed with a standardized experimental diet in a constant temperature environment, with unlimited drinking water.

[0033] Grouping of animals: Divide 30 mice into 5 groups: ① normal control group 6; ② uric acid nephropathy model group 6; ③ fisetin treatment group (50mg / kg / d and 100mg / kg / d) 6 ④ positive control allopurinol treatment group (10mg / kg / d) 6.

[0034] Modeling method: According to the weight of the mouse, the proportion of adenine 160mg / kg and potassium oxonate 2500mg / kg was mixed with distilled water to make a suspension with a final concentration of 80g / L, and the next day was administered orally in the morning and evening. For 28 consecutive days, an animal model of hyperuricemia renal damage was established. After 28 days, the mice were sacrificed, blood was collected from th...

Embodiment 2

[0046] Embodiment 2 The effect of fisetin in treating uric acid nephropathy

[0047] Experimental animals: SPF grade male C57BL / 6J mice. At least 1 week before the experiment, the rats were fed with a standardized experimental diet in a constant temperature environment, with unlimited drinking water.

[0048] Grouping of animals: Divide 24 mice into 4 groups: ① normal control group 6; ② uric acid nephropathy model group 6; ③ fisetin treatment group (100mg / kg / d) 6; ④ allopurinol treatment Group (10mg / kg / d) 6. Modeling method: According to the weight of the mouse, the proportion of adenine 160mg / kg and potassium oxonate 2500mg / kg was mixed with distilled water to make a suspension with a final concentration of 80g / L, and the next day was administered orally in the morning and evening. For 14 consecutive days, an animal model of hyperuricemia renal damage was established. After 28 days, the mice were sacrificed, blood was collected from the orbital venous plexus, and kidney ti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of fisetin in preparation of a medicine for preventing and treating uric acid nephropathy, and belongs to the field of medicine. The invention provides application of fisetin or salt thereof in preparation of the medicine for treating and / or preventing the uric acid nephropathy. Animal experiments prove that the fisetin can regulate protein expression of kidney urate transporters URAT1, OAT1, OAT3 and ABCG2, improve uric acid excretion rate and obviously reduce serum creatinine, blood urea nitrogen and blood uric acid levels, also has an effect of inhibiting renal interstitial fibrosis, can obviously reduce expression quantities of fibrosis-related proteins such as alpha-SMA, cologen I and fibronectin, has an exact prevention / treatment effect on the uric acid nephropathy and provides a new choice for clinical medication.

Description

technical field [0001] The invention relates to the use of fisetin in the preparation of medicines for preventing and treating uric acid nephropathy, which belongs to the field of medicine. Background technique [0002] Uric acid nephropathy is abnormal purine metabolism, kidney damage caused by elevated blood uric acid, early manifested as decreased urine concentration function, and then gradually decreased glomerular filtration rate, increased serum creatinine, leading to chronic renal insufficiency. In recent years, with the increasing incidence of hyperuricemia, the incidence of uric acid nephropathy has increased significantly year by year. Therefore, it is of great significance to seek effective drugs for the treatment of uric acid nephropathy. [0003] Previous studies have confirmed that reducing blood uric acid levels can delay the progression of kidney disease. Therefore, the treatment of uric acid nephropathy focuses on reducing blood uric acid levels and prevent...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P13/12A61P19/06
CPCA61K31/352A61P13/12A61P19/06
Inventor 马良任倩黄蓉双付平
Owner WEST CHINA HOSPITAL SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap